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and Susan D. Brain3
The cutaneous vasculature plays a key role in the pathophysiology of inflammatory skin diseases. The vascular
activity is under the control of the peripheral nervous system that includes locally released neuropeptides.
Recently, we detected receptors for the neuropeptide galanin in association with dermal blood vessels,
suggesting a role of the galanin-peptide-family in the regulation of the cutaneous microvasculature. Therefore,
we have investigated galanin and galanin-like peptide (GALP), a neuropeptide previously only considered to be
involved in metabolism and reproduction in the central nervous system, for vaso-modulatory activity in the
murine skin in vivo. Picomole amounts of intradermally injected galanin and GALP decreased cutaneous blood
flow and inhibited inflammatory edema formation. Both the full-length GALP (1–60) and the putative smaller
proteolytic fragment GALP (3–32) showed similar effects. These activities are most likely mediated by galanin
receptors galanin receptor subtype 2 (GalR2) and/or galanin receptor subtype 3 (GalR3), because reverse
transcription-PCR analysis of murine skin revealed messenger RNA (mRNA) expression of GalR2 and GalR3 but
not of galanin receptor subtype 1. The lack of galanin receptor mRNAs in endothelial and smooth muscle cells
indicates a neuronal localization of these receptors around the vessels. These results indicate functional activity
of GALP in the periphery in vivo and suggest a potential role as an inflammatory modulator.
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INTRODUCTION
The skin has an essential protective function in responding to
challenges from the environment. Cutaneous nerves transmit
nociceptive information to the central nervous system and
release biologically active neuropeptides (McDonald et al.,
1996). The efferent activities of sensory nerves, mediated via
neuropeptides such as substance P (SP) and calcitonin gene-
related peptide (CGRP), may contribute to the physiological
and pathophysiological modulation of skin responses
(Hokfelt and Ljungdahl, 1971; Brain, 1997).
Galanin is a 29 (30 human) amino-acid peptide involved
in a variety of peripheral and central physiological and
pathophysiological processes (Bartfai et al., 1993), including
secretion of hormones (McDonald et al., 1985; Bauer et al.,
1986), inhibition of cardiac vagal action (Ulman et al., 1994),
mitogenic properties (Sethi et al., 1992; Wynick et al., 1993),
and analgesic effects in response to nerve injury (Wiesenfeld-
Hallin et al., 1992).
A second peptide of the galanin family, galanin-like
peptide (GALP) shares the amino acids at position 9–21 with
the first 13 amino acids of galanin, which are required to
activate galanin receptors. The sequence of GALP (1–60)
contains a potential proteolytic cleavage site between two
basic amino acids at position 33, which might lead to shorter
C-terminally amidated peptides. In addition, the first two
amino acids of human GALP could be potentially removed
by dipeptidyl dipeptidase IV (Lang et al., 2005). Like galanin,
GALP has potent species-specific and time-dependent effects
in the central nervous system and has been suggested to
constitute a link between metabolism and reproduction
(Gottsch et al., 2004). To our knowledge, GALP has not
been shown to possess biological activity in the periphery.
The effects of galanin and GALP are mediated by G-protein-
coupled receptor subtypes, which are uniquely distributed
throughout the central nervous system and periphery (Burgevin
et al., 1995; Fathi et al., 1998; Kolakowski et al., 1998).
Galanin has high affinity for all three galanin receptor sub-
types, whereas GALP (1–60) displays high affinity only for
galanin receptor subtype 2 (GalR2) and galanin receptor
subtype 3 (GalR3) (Ohtaki et al., 1999; Berger et al., 2004).
Recently, it was shown that GALP (3–32) is a more potent
agonist on the GalR2 than the full-length peptide in neuro-
blastoma cells expressing the GalR2 (Lang et al., 2005).
ORIGINAL ARTICLE
716 Journal of Investigative Dermatology (2007), Volume 127 & 2006 The Society for Investigative Dermatology
Received 20 December 2005; revised 25 July 2006; accepted 30 July 2006;
published online 5 October 2006
1Department of Pediatrics, Paracelsus Private Medical University Salzburg,
Salzburg, Austria; 2Department of Dermatology, Paracelsus Private Medical
University Salzburg, Salzburg, Austria and 3Cardiovascular Division,
Kings College London, New Hunt’s House, Guy’s Campus, London, UK
Correspondence: Dr Barbara Kofler, Department of Pediatrics, Paracelsus
Private Medical University Salzburg, Muellner Hauptstr. 48, Salzburg A-5020,
Austria. E-mail: b.kofler@salk.at
Abbreviations: CGRP, calcitonin gene-related peptide; GALP, galanin-like
peptide; GalR2, galanin receptor subtype 2; GalR3, galanin receptor subtype
3; i.d., intradermally; mRNA, messenger RNA; RT, reverse transcription;
SP, substance P
The upregulation of galanin and galanin-binding sites in
rat skin upon inflammation indicates a role of the galanin
system in the plasticity of the cutaneous microvasculature
(Ji et al., 1995). Accordingly, galanin inhibits plasma
extravasation induced by antidromic C-fiber stimulation in
the rat hind paw (Xu et al., 1991) and histamine-induced
plasma extravasation in the pigeon skin (Jancso et al., 2000).
Furthermore, galanin-overexpressing mice showed a signifi-
cant decrease in plasma extravasation upon activation of
neurogenic inflammation following mustard oil treatment
(Holmberg et al., 2005). Consistent with these vascular
effects, we were able to demonstrate that galanin-binding
sites are present around blood vessels (Kofler et al., 2004).
Although there is evidence for a role of galanin in
modulating inflammatory edema in the periphery, the
possible functional significance of GALP in the periphery
has not been investigated. Moreover, the mechanism of
edema formation and the galanin receptor subtype involved,
are so far unclear. The purpose of this study was to analyze
the effects of galanin and GALP on cutaneous microvascu-
lature in mice. We have examined the ability of galanin and
GALP to modulate inflammatory edema formation and blood
flow in the murine skin in vivo. We have also examined the
skin for the presence of galanin receptors, that both galanin
and GALP can mediate their effects through.
RESULTS
Effects of galanin and GALP peptides on inflammatory edema
formation
Plasma extravasation was induced in skin by the coinjection
of the potent mediator of increased microvascular perme-
ability SP and the vasodilator CGRP, which act in a
synergistic manner to induce an acute inflammatory
edema in skin (Brain and Williams, 1985; Cao et al., 1999)
(Figure 1a). The b-adrenergic anti-permeability agent sal-
butamol (Teixeira et al., 1995) was used (Figure 1a), and the
potent vasoconstrictor endothelin (Brain et al., 1989) as
positive controls for the assay. It can be seen that galanin, at a
1 pmol dose, acted in a similar manner to endothelin to
abolish this edema. The effect of the full-length mature GALP
(1–60), the truncated peptides (1–32) and (3–32), as well as the
peptide fragment GALP (19–37), which lacks the galanin
receptor-binding domain, were also examined at a dose of
10 pmol/site for their ability to modulate edema formation
(Figure 1a). Although GALP (1–60) and GALP (3–32) demon-
strated an inhibitory effect, GALP (1–32) exhibited a lesser but
albeit significant inhibitory response and GALP (19–37) was
inactive (Figure 1a).
Further studies were then carried out to learn the dose-
dependent activities. Results for galanin are shown in
Figure 2, where galanin (0.1–10 pmol) acted in a dose-
dependent manner to inhibit edema formation, although
higher doses had less effect, giving a bell-shaped dose–
response curve. The ability of galanin to inhibit non-
neurogenic edema formation was investigated through the
study of histamine coinjected with CGRP-induced responses.
Figure 1b shows that galanin also inhibited histamine- and
CGRP-induced edema formation.
The dose-related effect of the two GALP peptides that
showed potent anti-edema activity, GALP (1–60) (1–100 pmol)
and GALP (3–32) (1–100 pmol) is shown in Figure 3. Again
bell-shaped dose–response curves were observed.
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Figure 1. Effects on inflammatory edema of the galanin-peptide-family.
(a) Edema formation was induced by i.d. injection of SP (300 pmol) and
CGRP (10 pmol), and the effect of coinjected salbutamol, endothelin-1
(n¼4), and galanin peptides (n¼ 6) is shown. Results are expressed as plasma
extravasation (ml/g), mean7SEM measured by the 125I-BSA method.
Responses that are significantly different from the corresponding SPþCGRP-
treated sites are shown (*Po0.05, **Po0.01; Dunnett’s). (b) Edema formation
was induced by histamine (3 nmol) and CGRP (10 pmol), and the effect of
coinjected galanin (3 pmol) is shown. Results are expressed as plasma
extravasation (ml/g), mean7SEM (n¼ 4) measured by the 125I-BSA method.
Responses that are significantly different from the corresponding
histamineþCGRP-treated sites (**Po0.01; Dunnett’s).
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Figure 2. The dose-related effect of galanin on edema formation induced by
i.d. injected SP (300 pmol) with CGRP (10 pmol). The response to increasing
doses of galanin (0.1–10 pmol) coinjected with SPþCGRP is shown as
% inhibition (mean7SEM.) of edema formation measured by the 125I-BSA
method. (n¼ 10). Responses that are significantly different from the
corresponding SPþCGRP-treated sites are shown (**Po0.01; Dunnett’s).
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The anti-edema effect of GALP (3–32) was confirmed using
a second technique (Evans Blue) to assess plasma extravasa-
tion (Figure 3c).
Effect of galanin and GALP peptides on skin blood flow
There are two obvious mechanisms via galanin peptides
could be acting to modulate inflammatory edema formation.
Either by inhibition of microvascular permeability (as
salbutamol) or as an indirect mechanism through reduction
of skin blood flow (as endothelin). To investigate possible
effects on blood flow, a 99 m technetium clearance
technique was utilized. Injection of galanin, GALP (1–60),
and GALP (3–32) all induced dose-dependent reductions in
inhibiting cutaneous blood flow (Figure 4; data for GALP
1–60 not shown). Figure 5 shows the expected lack of effect
of salbutamol, and the potent constrictor effect of endothelin-
1, and again GALP (1–32) was not effective (Figure 5).
Expression of galanin receptor subtypes
Reverse transcription (RT)-PCR analysis of dorsal murine skin
messenger RNA (mRNA) revealed no expression of galanin
receptor subtype 1 (Figure 6). GalR2 was consistently
expressed at substantial levels (Figure 6). GalR3 was detected
at low levels of mRNA expression (Figure 6). To determine
which cell types are expressing galanin receptor mRNA in the
microcvasulature, endothelial and smooth muscle cells were
separately used for galanin receptor-specific RT-PCR analysis.
Neither primary human endothelial cells (human dermal
microvascular endothelial cell) nor smooth muscle cells
(human umbilical artery smooth muscle cell) showed an
expression of galanin receptor subtype 1, GalR2, or GalR3
mRNA (data not shown). This finding was also supported
by a receptor membrane-binding study. Both cell types
were below the detection limit, which was defined
as p0.006 pmol bound galanin/mg membran protein. As
a control for the assay, SH-SY5Y/GalR2 were used with a
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Figure 3. Effect of GALP on inflammatory edema. Edema formation was
induced in response to i.d. injected SP (300 pmol) with CGRP (10 pmol). The
response in increasing doses of (a) GALP (1–60) (n¼ 6) and (b) GALP (3–32)
(n¼8) coinjected with SPþCGRP is shown as % inhibition (mean7SEM.) of
edema formation measured by the 125I-BSA method. Responses that are
significantly different from the corresponding SPþCGRP-treated sites are
shown (*Po0.05, **Po0.01; Dunnett’s). (c) The effect of GALP (3–32)
(10 pmol) on plasma extravasation induced by SPþCGRP as observed by
Evans Blue. Note that the intensity of blueing to SPþCGRP is reduced in the
presence of GALP (3–32). GALP (3–32) alone had no effect when compared to
vehicle.
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Figure 4. The dose-related effect of galanin and GALP on blood flow. The
dose–response effect of (a) galanin (n¼ 8) and (b) GALP (3–32) (n¼ 10) is
shown as decrease in % clearance (mean7SEM) compared with vehicle
(Tyrode-injected) skin. Results that are significantly different from
Tyrode-injected sites are shown (*Po0.05; **Po0.01).
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Figure 5. Effect of galanin and GALP peptides on blood flow in cutaneous
dorsal microvasculature. The responses of salbutamol and ET-1 as negative
and positive controls, respectively, are shown alongside responses of the
most potent concentration (according to Figure 4) of galanin and GALP
peptides (GALP (1–60), GALP (1–32), and GALP (3–32)). Responses are
shown as decrease in % clearance (mean7SEM) compared with vehicle
(Tyrode-injected) skin (n¼8). Results that are significantly different from
clearance at Tyrode-injected sites are shown (**Po0.01).
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binding capacity of 3.270.3 pmol bound galanin/mg mem-
brane protein (data not shown).
DISCUSSION
This study demonstrates the potent ability of galanin and
GALP to inhibit inflammatory edema, which is most likely
secondary to vasoconstricton and inhibition of blood flow in
the cutaneous microvasculature. Thus, we show that either
the full-length peptide GALP (1–60) or GALP (3–32) is able to
exert vasoactive effects in the cutaneous microcirculation.
There is evidence that galanin inhibits plasma extravasa-
tion in experimental models of neurogenic inflammation
induced either chemically or by C-fiber stimulation (Xu et al.,
1991; Green et al., 1992; Holmberg et al., 2005), and that
SP-induced plasma extravasation was inhibited by galanin in
the rat hind paw (Xu et al., 1991). Galanin-induced inhibition
of plasma extravasation could be mediated by presynaptic or
postsynaptic effects. Previously, galanin has been suggested
to modulate neurogenic edema formation via a presynaptic
mechanism by inhibiting release of SP and CGRP (Holmberg
et al., 2005). The experiments presented in our work utilizing
an experimental design with coinjection of SP and CGRP
with galanin or GALP indicate that the effect of galanin
on plasma extravasation is primarily a postsynaptic effect in
our system.
Possible downstream postsynaptic consequences could be
an interaction with the signaling of SP and CGRP, or a direct
vasoconstrictor activity of galanin. A first indication of an
involvement of galanin in the regulation of skin blood flow
came from the observation that mustard oil-mediated
vasodilatation in pigeon skin was potentiated by a galanin
antagonist (Santha et al., 1999). The vasoconstrictor potential
of galanin was confirmed in the hamster cheek pouch,
measured by the change of arteriolar diameter (Dagar et al.,
2003). This group found a similar potent vasoconstrictor
effect of human galanin when administered alone as
presented in this study, but also importantly that micelle
formation can amplify its vasoactive effects in vivo. In our
studies, a direct vasoactive effect was supported by a series of
experiments with histamine. Histamine, a potent mediator of
increased microvascular permeability, was co-injected with
vasodilator CGRP to induce edema formation. This edema
formation was inhibited by galanin coinjection. In further
support of our findings, Holmberg et al. (2005) have reported
that galanin-overexpressing mice show reduced edema
formation following chemical stimulation of neurogenic
inflammation in the mouse paw, although they did not
measure blood flow changes. To further clarify the vasocon-
strictive potency of galanin and GALP, skin blood flow was
measured using a 99 m technetium clearance assay, which
was initially developed in order to assess the vasoconstrictor
potential of the neuropeptide Y (Chu et al., 2003). In this
assay, we show that galanin, GALP (1–60), and GALP (3–32)
decreased skin blood flow and inflammatory edema, whereas
salbutamol, a b2-adrenergic receptor agonist which decreases
blood vessel leakiness (Kwan et al., 2001), was only active in
the edema model. This suggests that the primary activity of
galanin, GALP (1–60), and GALP (3–32) is that of cutaneous
vasoconstriction. However, we cannot rule out the possibility
of a concomitant permeability decrease.
Pharmacologically, the galanin and the GALP effects
showed bell-shaped dose–response curves in the plasma
extravasation and vasoconstriction assays. It is possible that
whereas at lower doses galanin is decreasing in blood flow, at
higher doses other mechanisms mediating direct effects in
promoting vascular permeability become active.
We have recently shown the presence of galanin-binding
sites in human skin. They were detected in a high density
around small vessels, indicating that galanin receptors
located around these vessels mediate the vascular activity
of galanin (Kofler et al., 2004). The type of galanin receptor
could not be specified by the galanin receptor autoradio-
graphy used. In this study, we demonstrate that dermal
endothelial and smooth muscle cells do not express galanin
receptors. These observations suggest that galanin receptors
around blood vessels in the human dermal microvasculature
are most likely located on neurons surrounding the vessels,
indicating that the effect on the dermal microvasculature is
indirect owing to mediators secondarily released by other
cells (e.g. nerve cells). However, we cannot exclude that
species- (human/mouse) and tissue-specific (skin/umbilical
cord) differences of galanin receptor location exist.
We show that the potency order of galanin peptide
fragments on edema formation was as follows: galanin
oGALP (3–32)oGALP (1–60)5GALP (1–32), and this is in
accordance with the affinities for the human GalR2 receptor
reported previously (Lang et al., 2005). Moreover, the
substantial expression of GalR2 in the murine skin further
implies a more likely GalR2 than GalR3-mediated mechan-
ism. In other model systems, GalR2 is upregulated following
inflammation whereas galanin receptor subtype 1 is down-
regulated, suggesting that under inflammatory conditions,
there may be preferential activity of the GalR2 receptor
(Xu et al., 1996).
We demonstrate here, that active members of the galanin
family of peptides possess activities that are in the region of
10- to 100-fold more potent than those of the established
potent constrictor agent neuropeptide Y (Chu et al., 2003).
Thus, our findings suggest a far-reaching influence in the
pathophysiology of inflammatory skin disorders and should
prompt experiments evaluating the therapeutic potential of
galanin and GALP in the skin.
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Figure 6. RT-PCR analysis of murine skin. RT-PCR analysis of murine skin
mRNA for galanin receptor subtype 1, GalR2, and GalR3 expression. Lane 1:
100 bp ladder; lane 2: negative control; lane 3–5: dorsal murine skin of three
different animals; and lane 6: murine brain cDNA.
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MATERIALS AND METHODS
Mice
Normal female CD-1 mice (22–27 g, 8–12 weeks) were obtained
from Charles River, UK. All mice were maintained on normal diet,
with free access to food and water, in a climatically controlled
environment. Animals were anesthetized with urethane (25% w v1;
2.5 g kg1 intraperitoneally) and the dorsal skin was shaved.
Injection sites were chosen according to a randomized site pattern
on the dorsal skin of the anesthetized mouse. Experiments involving
mice were conducted under the Animals (Scientific Procedures) Act,
1986.
Cell lines
Primary human dermal microvascular endothelial cells were isolated
from normal adult foreskin and cultured as described previously by
Nguyen et al. (2002). Primary human umbilical artery smooth
muscle cells were purchased from Promocell (Heidelberg, Germany)
and cultured in smooth muscle basal medium 2 (Promocell,
Heidelberg, Germany) at 371C in a humified atmosphere of 5%
CO2. Stable transfected SH-SY5Y neuroblastoma cells with the
human galanin receptor GalR2 (SH-SY5Y/GalR2) were cultivated as
recently described (Berger et al., 2004). As the galanin receptor
expression is under control of a tetracycline-regulated expression
system (T-Rex System, Invitrogen Corporation, CA), receptor
expression was induced overnight with 1mg/ml tetracycline.
Agents
SP, CGRP, endothelin-1, and salbutamol were from Sigma (Poole,
UK), as well as all others agents unless specified. Galanin (rat) and
GALP (1–60) (human) were purchased from Bachem (Bubendorf,
Switzerland). GALP (1–32)-amide (human) GALP (3–32)-amide
(human), GALP (19–37) (human) were custom synthesized by
NeoMPS Inc. (Strasbourg, France). All peptides were dissolved in
distilled water. The stock solutions (10 nM) were stored at 201C and
further diluted in Tyrode’s solution (137 mM NaCl, 2.7 mM KCl,
0.5 mM MgCl2, 0.4 mM NaH2PO4, 11.9 mM NaHCO3, and 5.6 mM
glucose) just prior use.
Measurement of inflammatory edema formation
Plasma extravasation was used as an index of inflammatory edema
formation and measured as described previously (Cao et al., 1999).
Briefly, test agents (Galanin, GALP (1–60), GALP (1–32), GALP
(3–32), GALP (19–37), endothelin-1, and salbutamol) were diluted in
Tyrode’s solution and stored on ice. 125I-BSA (45 kBq in 100 ml of
saline) was administered intravenously into the tail vein, and
5 minutes later test agents (50 ml/site) were injected intradermally
(i.d.). Plasma extravasation was allowed for 30 minutes and then a
blood sample (0.5 ml) in a heparine-coated syringe was obtained via
cardiac puncture and centrifuged at 10,000 g for 4 minutes to obtain
plasma. The mice were then killed, the dorsal skin was removed, and
the injected sites punched out (8 mm). The amount of plasma
extravasated (ml g1 tissue) was calculated by comparing the amount
of radioactivity in each skin site with that in 100 ml plasma from the
same animal.
In a separate set of experiments, edema formation was observed
by the extravascular accumulation of intravenously injected Evans
Blue (0.1 ml of 2.5% w v1 in saline) that binds to endogenous
plasma albumin. After 5 minutes, test agents (50 ml in Tyrode
solution) were injected i.d. Animals were left for 30 minutes to
allow plasma extravasation to occur. Animals were then killed by
cervical dislocation. Dorsal skin was removed and photographed to
identify sites of plasma extravasation.
Measurement of skin blood flow
Blood flow changes were measured using a 99 m technetium
clearance technique (Chu et al., 2003). Briefly, test agents (Galanin,
GALP (1–60), GALP (1–32), GALP (3–32), endothelin-1, and
salbutamol) were made up in Tyrode’s solution and an equal
amount of 99 m technetium (aprox. 200 kBq) was added to all
samples, and kept on ice until use. Test agents (50 ml/site) were
injected i.d., with an identical amount placed into a vial for
measurement of the total radioactivity. The mouse was killed after a
clearance period (15 minutes) and the skin was removed and the
injected sites punched out for measurement of the remaining
radioactivity. Initially, the amount of 99 m technetium cleared from
each injection-site was calculated by comparing counts in skin with
counts in the respective paired aliquot of total radioactivity. From
this, the clearance at test agent-injected sites was then calculated by
comparing with the Tyrode-value (which was normalized to 100 for
each experiment), and expressed as % change in clearance
compared to Tyrode, with positive numbers indicating a decreased
blood flow.
Receptor-binding assay
Membrane preparation and radioligand-binding assay were per-
formed as described previously (Berger et al., 2004). Radio-labeled
galanin binding to membrane preparation (15 mg) was carried out in
duplicates in a total volume of 120 ml of binding buffer containing
50 pM [125I]galanin (2.000 Ci/mmol; Amersham Pharmacia Biotech
(Little Chalfont, UK)) and non-specific binding was determined in the
presence of 1mM human galanin.
RT-PCR analysis
Murine skin tissues where homogenized within 10 minutes after
withdrawal of a freshly killed animal in Tri Reagent (Molecular
Research Center Inc., Cincinnati, OH), using an Ultra-Turrax T25
(IKA Werke GmbH & Co., KG, Germany). Total RNA from tissues
and cell lines was isolated according to the instructions of
the manufacturer. RNA (1mg) was reverse transcribed using 200 U
SUPERSCRIPT IITM reverse transcriptase (Life Technologies Inc.,
Gaithersburg, MD). PCR amplification using 100 ng of cDNA was
performed using Thermo Start polymerase (ABgene, Surrey, UK) in
the presence of 10 pmol of each primer. Primers and PCR conditions
are listed as Supplementary Material in Table S1. The PCR products
were analyzed by electrophoresis on a 2% agarose gel stained with
ethidium bromide.
Statistical analysis
Results for functional studies are shown mainly as mean7SEM.
Statistical analyses were performed on original data by one-way
analysis of variance, followed by Dunnett’s or Bonferroni multiple
comparison test. Po0.05 was considered as significant. N represents
the number of animals.
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